Therapeutic options for patients with advanced-stage melanoma have been increased in the last years, and approval of new therapeutic agents such as the checkpoint inhibitors (anti-CTLA4 and anti-PD1 antibodies) and BRAF/MEK inhibitors has opened new expectations for survival. The gene discussed is BRAF; the disease is melanoma.